enzalutamide (Xtandi) -

enzalutamide (Xtandi)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Renal and urologic disorders
Summary
The SMC have accepted use of enzalutamide in NHS Scotland for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
UKMi comment
Separately, NICE Technology Appraisal Guidance TA377 recommends enzalutamide as an option for treating metastatic hormone relapsed prostate cancer in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.
Related links: NICE TA377